| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,940,000 |
| Market
Cap: |
202.02(M) |
| Last
Volume: |
38,851 |
Avg
Vol: |
19,828 |
| 52
Week Range: |
$1.63 - $1.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
371,517 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,315,104 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
11 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zhang Larry |
President |
• – – |
2020-07-22 |
4 |
B |
$1.90 |
$38,291 |
D/D |
20,153 |
20,153 |
2.74 |
28% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-07-22 |
4 |
B |
$1.90 |
$2,280,000 |
I/I |
1,200,000 |
7,532,347 |
2.64 |
28% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-07-22 |
4 |
B |
$1.90 |
$5,609,609 |
D/D |
2,952,426 |
4,836,523 |
3.23 |
28% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-05-20 |
4 |
B |
$2.37 |
$133,820 |
D/D |
56,464 |
1,884,097 |
3.23 |
-37% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-05-19 |
4 |
B |
$2.03 |
$60,496 |
D/D |
29,801 |
1,827,663 |
3.23 |
-12% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-05-18 |
4 |
B |
$2.02 |
$684,643 |
D/D |
338,932 |
1,797,832 |
3.23 |
-13% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-05-15 |
4 |
B |
$1.82 |
$182,000 |
D/D |
100,000 |
1,458,900 |
3.23 |
-13% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2020-03-27 |
4 |
B |
$2.08 |
$14,310 |
D/D |
6,880 |
1,358,900 |
2.81 |
-15% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-03-26 |
4 |
B |
$2.09 |
$685,719 |
D/D |
328,095 |
1,352,020 |
3.23 |
-14% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-03-25 |
4 |
B |
$1.94 |
$381,012 |
D/D |
196,398 |
1,023,925 |
3.23 |
7% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-03-19 |
4 |
B |
$1.57 |
$368,146 |
I/I |
234,488 |
6,332,347 |
2.64 |
7% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-03-18 |
4 |
B |
$1.52 |
$762,009 |
I/I |
501,322 |
6,097,859 |
2.64 |
26% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2020-03-17 |
4 |
B |
$1.50 |
$396,288 |
I/I |
264,192 |
5,596,537 |
2.64 |
20% |
|
| Wealth Strategy Holding Ltd |
10% Owner |
– – • |
2019-12-30 |
4 |
OE |
$1.69 |
$834,568 |
D/D |
493,827 |
9,087,888 |
|
- |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2019-12-16 |
4 |
OE |
$1.69 |
$632,602 |
I/I |
374,321 |
5,332,345 |
|
- |
|
| He Wei-Wu |
Chief Executive Officer |
• • • |
2019-08-16 |
4 |
B |
$3.20 |
$64,000 |
D/D |
20,000 |
827,527 |
3.23 |
- |
|
| He Wei-Wu |
Chief Executive Officer |
• • • |
2019-08-14 |
4 |
B |
$3.17 |
$507,200 |
D/D |
160,000 |
807,527 |
3.23 |
- |
|
| Spectrum Pharmaceuticals Cayman, L.p. |
10% Owner |
– – • |
2019-04-02 |
4 |
D |
$3.38 |
$5,074,200 |
D/D |
(1,500,000) |
5,397,413 |
|
- |
|
| Wong Cynthia |
COO, Gen Counsel & Secretary |
• – – |
2019-01-14 |
4 |
D |
$3.79 |
$11,749 |
D/D |
(3,100) |
29,685 |
|
- |
|
| Wong Cynthia |
COO, Gen Counsel & Secretary |
• – – |
2019-01-14 |
4 |
OE |
$1.76 |
$26,400 |
D/D |
15,000 |
32,785 |
|
- |
|
| He Wei-Wu |
Director |
– • • |
2018-12-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
200,000 |
647,527 |
|
- |
|
| Shong Hugo |
10% Owner |
– – • |
2018-11-13 |
4 |
OE |
$1.69 |
$2,872,583 |
D/D |
1,699,753 |
10,198,518 |
|
- |
|
| Capitelli Sara B |
VP Fin & Principal Account Off |
• – – |
2018-07-12 |
4 |
D |
$7.49 |
$199,215 |
D/D |
(26,600) |
0 |
|
- |
|
| Capitelli Sara B |
VP Fin & Principal Account Off |
• – – |
2018-07-12 |
4 |
D |
$7.49 |
$62,910 |
D/D |
(8,400) |
26,600 |
|
- |
|
| Capitelli Sara B |
VP Fin & Principal Account Off |
• – – |
2018-07-12 |
4 |
OE |
$1.99 |
$69,475 |
D/D |
35,000 |
35,000 |
|
- |
|
159 Records found
|
|
Page 2 of 7 |
|
|
